Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Xitix** is a brand name for a vitamin C (ascorbic acid) preparation developed by Woelm Pharma, primarily used for the prevention and treatment of hypo- and avitaminosis C. Ascorbic acid is essential for intracellular collagen formation, strengthening teeth, bones, and capillary walls, while participating in redox reactions, tyrosine metabolism, folic acid conversion, carbohydrate/lipid/protein synthesis, iron metabolism, and cellular respiration; it enhances infection resistance, iron absorption, and acts as an antioxidant. For systemic use, it addresses increased vitamin C needs during growth, pregnancy, lactation, heavy loads, fatigue, recovery from illness, and winter infection risk; intravaginally, it normalizes vaginal pH and microflora in chronic/recurrent vaginitis. Administered orally, IM, IV, or intravaginally, with dosages of 25-75 mg/day for prevention and 250 mg/day or more for treatment.[1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xitix.